ESRD Impairs Nonrenal Clearance of Fexofenadine but not Midazolam
Open Access
- 1 October 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 20 (10), 2269-2276
- https://doi.org/10.1681/asn.2009010082
Abstract
ESRD can affect the pharmacokinetic disposition of drugs subject to nonrenal clearance. Cytochrome P450 (CYP) enzymes, including CYP3A, and multiple intestinal and hepatic drug transporters are thought to mediate this process, but the extent to which kidney disease alters the function of these proteins in humans is unknown. We used midazolam and fexofenadine to assess CYP3A (intestinal and hepatic) and drug transport, respectively, in patients with ESRD and healthy control subjects. We evaluated the effect of uremia on CYP3A and transporter expression in vitro by incubating normal rat hepatocytes and enterocytes with serum drawn from study participants. ESRD dramatically reduced nonrenal transporter function, evidenced by a 63% decrease in clearance (P < 0.001) and a 2.8-fold increase in area under the plasma concentration–time curve for fexofenadine (P = 0.002), compared with control subjects. We did not observe significant differences in midazolam or 1′-hydroxymidazolam clearance or area under the curve after oral administration, suggesting that CYP3A function is not changed by ESRD. Changes in hepatocyte and enterocyte protein expression in the presence of uremic serum were consistent with in vivo results. These findings demonstrate a mechanism for altered drug disposition in kidney disease, which may partially account for the high rates of drug toxicity in this population.This publication has 45 references indexed in Scilit:
- Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse LiversDrug Metabolism and Disposition, 2008
- Prevalence of Chronic Kidney Disease in the United StatesPublished by American Medical Association (AMA) ,2007
- Effects of Chronic Renal Failure on Liver Drug TransportersDrug Metabolism and Disposition, 2007
- Multidrug Resistance-Associated Protein 2 Is Primarily Responsible for the Biliary Excretion of Fexofenadine in MiceDrug Metabolism and Disposition, 2007
- Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in RatsThe Journal of pharmacology and experimental therapeutics, 2006
- Hemodialysis Acutely Improves Hepatic CYP3A4 Metabolic ActivityJournal of the American Society of Nephrology, 2006
- IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAYDrug Metabolism and Disposition, 2006
- Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and womenPharmacogenetics, 2003
- Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediatorsBritish Journal of Pharmacology, 2002
- Unidimensional Scale for DementiaDementia and Geriatric Cognitive Disorders, 2001